Abstract
While molecular-targeted drugs have demonstrated strong therapeutic efficacy against diverse diseases such as cancer and infection, the appearance of drug resistance associated with genetic variations in individual patients or pathogens has severely limited their clinical efficacy. Therefore, precision medicine approaches based on the personal genomic background provide promising strategies to enhance the effectiveness of molecular-targeted therapies. However, identifying drug resistance mutations in individuals by combining DNA sequencing and in vitro analyses is generally time consuming and costly. In contrast, in silico computation of protein-drug binding free energies allows for the rapid prediction of drug sensitivity changes associated with specific genetic mutations. Although conventional alchemical free energy computation methods have been used to quantify mutation-induced drug sensitivity changes in some protein targets, these methods are often adversely affected by free energy convergence. In this paper, we demonstrate significant improvements in prediction performance and free energy convergence by employing an alchemical mutation protocol, MutationFEP, which directly estimates binding free energy differences associated with protein mutations in three types of a protein and drug system. The superior performance of MutationFEP appears to be attributable to its more-moderate perturbation scheme. Therefore, this study provides a deeper level of insight into computer-assisted precision medicine.
Highlights
While molecular-targeted drugs have demonstrated strong therapeutic efficacy against diverse diseases such as cancer and infection, the appearance of drug resistance associated with genetic variations in individual patients or pathogens has severely limited their clinical efficacy
The present study compared MP-CAFEE and an alternative FEP protocol based on an alchemical mutation algorithm[23], MutationFEP, in terms of performance in predicting mutation-induced changes in drug sensitivity using three protein systems: ALK with ALK tyrosine kinase inhibitor, a viral protein, H1N1–2009 neuraminidase (NA) with neuraminidase inhibitor, and aldose reductase (ALR2) with five drugs
The NA-oseltamivir cocrystal structure was obtained from the Protein Data Bank (PDB), and chain A of the tetramer in the deposited structure was used in the subsequent structure preparation
Summary
While molecular-targeted drugs have demonstrated strong therapeutic efficacy against diverse diseases such as cancer and infection, the appearance of drug resistance associated with genetic variations in individual patients or pathogens has severely limited their clinical efficacy. The present study compared MP-CAFEE and an alternative FEP protocol based on an alchemical mutation algorithm[23], MutationFEP, in terms of performance in predicting mutation-induced changes in drug sensitivity using three protein systems: ALK with ALK tyrosine kinase inhibitor (alectinib), a viral protein, H1N1–2009 neuraminidase (NA) with neuraminidase inhibitor (oseltamivir), and aldose reductase (ALR2) with five drugs. Because the latter protocol only perturbs intermolecular interactions involving the mutated residue(s), most protein-drug interactions are maintained during FEP simulations, potentially avoiding the end-point problem. MutationFEP is expected to become an invaluable computational tool that could accelerate the development of new precision medicine therapies
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.